Date: 2014-05-28
Type of information: Private placement
Company: Moberg Pharma (Sweden)
Investors: undisclosed Swedish and international institutional qualified investors
Amount: SEK 60 million (€6.64 million)
Funding type: private placement of new shares
Planned used: The proceeds from the directed share issue strengthens Moberg Pharma’s balance sheet and enables value-creating investments, including acquisitions of additional brands/products as well as preparations for licensing and development of product candidates in clinical phase.
Others: * On May 28, 2014, Moberg Pharma has announced that the company has completed a directed share issue of 2.1 million new shares, which brings SEK 60 million (€6.64 million) to the company before transaction costs. The new share issue, which was resolved by the Board of the company on May 27th, 2014 with authorization from the Annual General Meeting on May 13th, 2014, includes 2,068,965 new shares and has been directed to a limited group of Swedish and international institutional qualified investors at a price of SEK 29 per share through a private placement procedure. The subscription price has been set through a customary bookbuilding process. The subscription price entails a discount of approximately 7.3 percent in relation to the average daily price for the last 30 trading days as of the last day of trading before the decision to issue the new shares.The new share issue in Moberg Pharma increases the number of shares with 2,068,965 shares from 11,893,572 shares to 13,962,537 shares in total and increases the share capital by SEK 206,896.50 from SEK 1,189,357.20 to SEK 1,396,253.70 in total. The new share issue entails a dilution of approximately 15 percent.
Östersjöstiftelsen, the largest shareholder of the company, has in connection with the new issue lent 2,068,965 shares to ABG Sundal Collier to enable delivery of subscribed shares to investors. The lent out shares will be returned after registration of the share issue with the Swedish Companies Registration Office.
Therapeutic area:
